For PE Partners in Healthcare — Marketing DD + Infrastructure | ICG Enterprise

Schema: Service + FAQPage + Person Word count: ~2,200

Author: Abhash Kumar · Co-Founder, ICG · IIT BHU + IIM Bangalore · July 2026

What PE investors are finding in healthcare marketing DD

ICG conducts marketing due diligence for PE firms evaluating healthcare businesses. Across these engagements, the same five infrastructure gaps appear consistently. They are not always dealbreakers — but they are valuation inputs.

Gap 1 — CPQL is measured as CPL. The portfolio company reports a competitive CPL. When ICG maps the actual attended consultation rate, the real CPQL is 1.5–3× the reported CPL. The marketing efficiency narrative in the investment case is overstated. For PE firms that have CPQL benchmarks from comparable companies, this is immediately visible.

Gap 2 — Attribution infrastructure is incomplete. Standard pixel tracking misses 35–42% of conversions in iOS-heavy Indian urban markets. The portfolio company's attribution data is systematically incomplete. The Smart Bidding algorithms are optimising on a biased sample. The CPQL trajectory the company believes it is on may not be the trajectory the algorithm is generating.

Gap 3 — Compliance exposure is unmapped. At least one active campaign or website page that would not pass an NMC Section 6 review. For IVF portfolio companies: often a success rate claim in a Google Ads headline — directly prohibited under ART Act 2021 Section 26. A competitor-filed complaint converts this from a latent risk to an active regulatory event.

Gap 4 — No AEO/LLM position. The portfolio company has no measurement or strategy for AI Overview, ChatGPT, or Perplexity citation. With 18–22% of urban Indian patients starting healthcare research on AI tools — and this number doubling annually — this is a forward-looking patient acquisition gap.

yoda/02-aio-lab-rank-checker.png" alt="YODA AIO Lab Rank Checker — daily monitoring of AI Overview citation status for every tracked healthcare query" loading="lazy" decoding="async" style="width:100%;height:auto;display:block;">

Gap 5 — No limbo lead recovery. 28–34% of monthly leads sit unresponded-to at day 30. For a portfolio company spending ₹40 lakh/month in media, this represents ₹7–13 lakh in equivalent wasted media per month.

The 6-point PE marketing due diligence framework

ICG's DD framework (also available as the PE Healthcare Marketing DD Checklist PDF — /downloads/pe-healthcare-marketing-dd-checklist):

1. CPQL Baseline Audit: Is attendance rate tracked? Is real CPQL calculated at specialty level? What is the CPQL vs ICG benchmark for this specialty and city?

2. Attribution Infrastructure: Server-side CAPI deployed? CRM-to-media attribution chain complete? What % of consultation revenue is currently attributable?

3. Compliance Exposure Map: NMC Section 6 review complete? ART Act 2021 review (IVF)? Schedule J review (cardiac, oncology)? DPDP Act 2023 data audit?

4. AEO / LLM Position: AIO citation rate measured? LLM citation share by specialty? FAQPage schema implemented?

5. LTV Architecture: Retention rate by specialty? Cross-specialty referral capture rate? Package/subscription penetration?

6. Competitive Positioning: Google Maps position 1–3 for primary specialty + city? Branded search volume trend? Named-specialist depth (YouTube + AEO programme for key consultants)?

Scoring: 0–2 failures: minor cleanup, proceed. 3–4 failures: negotiate price adjustment, remediate in first 90 days. 5+: pre-close remediation sprint required.

The pre-fundraise infrastructure sprint

For portfolio companies approaching a Series B, ESOP, or strategic exit where the buyer will conduct marketing DD — ICG offers a 90-day pre-fundraise sprint:

Weeks 1–3: Compliance remediation (highest-priority gap for deal risk). NMC Section 6 review of all active creative and web copy. Immediate correction of non-compliant content. ART Act review for IVF businesses.

Weeks 4–6: Attribution infrastructure. Beacon CAPI deployment (Meta + Google). First server-side conversion events flowing. CRM lead source capture activated.

Weeks 7–9: CPQL baseline establishment. First real CPQL number (by specialty) available. Attribution rate moving from 47–62% baseline toward 65–72%.

Weeks 10–12: First clean attribution report. 30-day snapshot showing marketing-attributable revenue, CPQL by specialty, and improvement trajectory. This report goes into the investment memorandum.

The narrative for the deal: "Marketing infrastructure upgraded pre-close. Attribution improving from X% to Y% over [period]. CPQL trajectory: [baseline] → [month 12 target]." This turns a DD finding from a risk flag into a value-creation milestone.

Case study: PE-backed IVF chain

30 months into PE ownership, approaching Series B LP meeting. Marketing infrastructure: 5 disconnected CRMs, no unified attribution, reported CPL ₹1,840 (real CPQL ₹2,120 when ICG mapped attendance rates). PE operating partner: "marketing infrastructure must be investment-grade before Series B."

ICG Growth OS deployment: 12-month engagement.

Month 12 outcomes: CPQL ₹1,040 (51% below ₹2,120 baseline), MRR:CAC 12.6×, LLM citation rate 24% across target IVF queries, attribution infrastructure described by PE as "investment-grade" in the LP meeting deck.

PE partner post-meeting: "The CPQL trajectory was in the deck as a value-creation milestone."

(Anonymised. Full case: /case-studies/anonymised-pe-backed-ivf-chain-growth-os)

FAQ

Q: Does ICG work directly with PE operating partners or with the portfolio company management team? Both models work. The most effective structure: ICG engaged by the PE operating partner at the portfolio company level — with the operating partner receiving the monthly Agency OS report directly (in addition to the CMO). This gives the PE firm direct visibility into marketing performance without depending on the portfolio company's self-reporting.

Q: What does ICG charge for a marketing DD engagement? Marketing DD audit: ₹3–5 lakh (3-week engagement). Output: 6-point DD framework scorecard, CPQL benchmark comparison for the portfolio company's specialty and city, compliance exposure map, and remediation cost estimate. The DD audit fee is separate from any subsequent programme engagement.

Q: How does ICG's pre-fundraise sprint affect deal valuation? The most direct valuation impact: closing the attribution gap from 47% to 79% means the marketing P&L the buyer sees shows 79% of marketing contribution to revenue rather than 47%. If the portfolio company generates ₹100 crore in consultation revenue with 47% attributed at DD, the marketing investment case is built on ₹47 crore. At 79% attribution, it is built on ₹79 crore — a significantly stronger investment thesis. The EV/EBITDA multiple applied to the healthcare marketing-driven revenue portion varies by buyer, but the direction is unambiguous.

Downloadable: PE Healthcare Marketing Due Diligence Checklist → Download: /downloads/pe-healthcare-marketing-dd-checklist

Contact: /book?type=enterprise | +91 81302 26224 | contact@ichelonconsulting.com